78
Participants
Start Date
August 15, 2019
Primary Completion Date
January 17, 2024
Study Completion Date
January 17, 2024
BAY2416964
Oral application of study drug daily in a predefined dose escalation scheme.
BAY2416964
Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
Charité Campus Benjamin Franklin (CBF), Berlin
Hospital Universitario 12 de Octubre, Madrid
Greenville Health System, Greenville
Hospital Clínico Universitario de Valencia, Valencia
Universitätsklinikum Heidelberg, Heidelberg
University of Texas MD Anderson Cancer Center, Houston
Yale University School of Medicine, New Haven
"South Texas Accelerated Research Therapeutics , START San Antonio"
Princess Margaret Hospital-University Health Network, Toronto
CHU de Québec-Hôpital de l'Enfant-Jésus, Québec
Universitätsklinikum Carl Gustav Carus Dresden, Dresden
Institut Català d'Oncologia Hospitalet, L'Hospitalet de Llobregat
"Hospital Ramón y Cajal , Oncología"
"Hospital Universitario Virgen de la Victoria , Cardiology Department"
Royal Marsden NHS Trust (Surrey), Sutton
Beatson West of Scotland Cancer Centre, Glasgow
Christie Hospital, Manchester
Lead Sponsor
Bayer
INDUSTRY